Helix BioPharma Amends Acquisition Agreements to Finalise Share Consideration Ahead of Potential Financing

About this update from Helix Biopharma Corp.

[{"type":"text","content":"Helix BioPharma Amends Acquisition Agreements to Finalise Share Consideration Ahead of Potential Financing\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n December 6, 2024, (Toronto, Ontario) –\n \n\n TheNewswire –\n \n\n Helix BioPharma Corp.\n(TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)\n(“\n \n\n Helix\n \n\n ” or the “\n \n\n Company\n \n\n ”), a clinical-stage\nbiopharmaceutical company developing novel and unique therapies in the\nfield of immune-oncology, based on its proprietary technological\nCEACAM6 platform, DOS47, announces that, further to its news releases\ndated November 29, 2024 and December 2, 2024, it has entered into\namendment agreements with each of Laevoroc Immunology AG\n(“\n \n\n Laevoroc Immunology\n \n\n ”) and Laevoroc\nChemotherapy AG (“\n \n\n Laevoroc\nChemotherapy\n \n\n ”) to amend the consideration\npayable under the asset purchase agreements dated November 28, 2024,\nand November 30, 2024, respectively (the “\n \n\n Immunology Agreement\n \n\n ” and the “\n \n\n Chemotherapy Agreement\n \n\n ”).\n \n\n\n\n Pursuant to an amendment agreement between the Company\nand Laevoroc Immunology dated December 5, 2024, the Company and\nLaevoroc Immunology have agreed to amend the Immunology Agreement to\nset the number of common shares issuable upon closing at 11,555,076\ncommon shares, rather than a floating percentage of 16.5% of the\nnumber of issued and outstanding shares as of the closing date.\n \n\n\n\n Similarly, pursuant to an amendment agreement between\nthe Company and Laevoroc Chemotherapy dated December 5, 2024, the\nCompany and Laevoroc Chemotherapy have agreed to amend the\nChemotherapy Agreement to set the number of common shares issuable\nupon closing at 9,454,153 common shares, rather than a floating\npercentage of 13.5% of the number of issued and outstanding shares as\nof the closing date.\n \n\n\n\n The Company amended the terms as a result of a\npotential financing deal that may close before the closing of the\ntransactions, which, if consummated, would have led to unintended\ndilution and valuation adjustments. Management believes this approach\nallows the Company greater flexibility to negotiate financing terms\nwhile protect...

More updates from Helix Biopharma Corp.